Top Industry Leaders in the Endoscopic Retrograde Cholangiopancreatography Market
Latest Endoscopic Retrograde Cholangiopancreatography Companies Update
Nov 2023: The next-generation enterprise imaging platform from Fujifilm Healthcare Americas Corporation, a top supplier of diagnostic and enterprise imaging solutions, announced today that Synapse® 7x, the platform, has been authorized to operate on Department of Defense (DoD) networks in the United States and has been granted a Risk Management Framework (RMF) and Authority to Operate (ATO). After using Synapse® 5, the company's previous platform, Fujifilm, was granted an ATO for its improved platform for almost five years. Synapse 7x is a server-side rendering platform that is cloud-deployable and hardware-agnostic. It unifies data and imagery from cardiology, radiology, mammography, 3D, and other enterprise imaging solutions. Organizations connected to the DoD network will have access to a PACS platform that spans the whole company thanks to Synapse 7x, an enlargement of the radiology-specific PACS.
June 2023: In line with the company's corporate objective to streamline its product range by 2025, Becton, Dickinson, and Co. (BD) agreed to sell Steris plc its Surgical Instrumentation platform for $540 million. The V. Mueller, Snowden-Pencer, and Genesis goods are being divested along with three specialized manufacturing sites. Approximately 360 employees will be recruited by Steris through the portal. Subject to regulatory approval, the companies anticipate that the all-cash transaction will soon.
List of Endoscopic Retrograde Cholangiopancreatography Key companies in the market
- Olympus Corporation (Japan)
- Fujifilm Holdings, Corporation (Japan)
- STERIS PLC (UK)
- Cook Medical (US)
- Boston Scientific Corporation (US)
- CONMED Corporation (US)
- HOYA Group (Japan)
- Q3 Medical Devices Limited (Ireland)
- Ambu Inc. (Denmark)
- Medtronic Plc (Ireland)